The niacin challenge test: Clinical manifestation of altered transmembrane signal transduction in schizophrenia?

Biological Psychiatry

Volumn 41, Issue 5, 1997, Pages 507-513

  Hudson, Craig J ^a,c   Lin, Anna ^a   Cogan, Samantha ^a   Cashman, Frank ^a   Warsh, Jerry J ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

Author keywords

circulation; phospholipid; prostaglandin; schizophrenia; signal transduction

Indexed keywords

NICOTINIC ACID; PHOSPHOLIPID;

ADULT; AFFECTIVE NEUROSIS; ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROVOCATION TEST; SCHIZOPHRENIA; SIGNAL TRANSDUCTION; SKIN TEMPERATURE; VASODILATATION;

ADOLESCENT; ADULT; AGED; BIPOLAR DISORDER; FEMALE; HUMANS; MALE; MEMBRANE POTENTIALS; MIDDLE AGED; NIACIN; PHOSPHOLIPIDS; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; SIGNAL TRANSDUCTION; SKIN TEMPERATURE; SYNAPTIC MEMBRANES;

EID: 0031106358     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-3223(96)00112-6     Document Type: Article

References (28)

1. Albers M, Meurer H, Marki F (1993): Phospholipase A2 activity in serum of neuroleptic-naive psychiatric inpatients. Pharmacopsychiatry 26:94-98.
2. Bezchlibnyk-Butler KZ, Jeffries JJ, Martin BA (eds) (1994): Clinical Handbook of Psychotropic Drugs, 4th rev ed. Toronto: Hogrefe & Huber Publishers.
3. Cochran CD, Hale WD (1985): College student norms on the brief symptom inventory. J Clin Psychol 41:777-779.
4. Chouinard G, Ross-Chouinard A, Annable L, Jones B (1980): Extrapyramidal symptom rating scale. Can J Neurol Sci 7:233.
5. de Koning P, de Vries MH (1995): A comparison of the neuro-endocrinological and temperature effects of DU 29894, flesinoxan, sulpiride and haloperidol in normal volunteers. Br J Clin Pharmacol 39:7-14.
6. Endrenyi L, Mayank P (1991): Evaluation of two assumptions: Single straight line, and single normal distribution. Trends Pharmacol Sci 12:293-296.
7. Fielder F, Wolkin A, Rotrosen J (1986): Niacin-induced flush as a measure of prostaglandin activity in alcoholics and schizophrenics. Biol Psychiatry 21:1347-1350.
8. Ford GA, Katzir D, Blaschke TF, Hoffman BB (1991): Responsiveness of peripheral veins to vasodilators and the effect of nifedipine on alpha-adrenergic responsiveness in hypertension. Clin Pharmacol Ther 50:192-198.
9. Gattaz WF, Kollisch M, Thuren T, Virtanen J, Kinnunen P (1987): Increased plasma phospholipase-A2 activity in schizophrenic patients: Reduction after neuroleptic therapy. Biol Psychiatry 22:421-426.
10. Gattaz WF, Hubner C, Nevalaina T, Thuren T, Kinnunen P (1990): Increased serum phospholipase-A2 activity in schizophrenia: A replication study. Biol Psychiatry 28:495-501.
11. Glen A, Glen E, Horrobin D, et al (1994): A red cell membrane abnormality in a subgroup of schizophrenic patients: Evidence for two diseases. Schizophr Res 12:53-61.
12. Hamilton M (1960): A psychiatric rating scale for depression. J Neurol Neurosurg Psychiatry 23:56-62.
13. Horrobin DF (1980): Schizophrenia: A biochemical disorder. Biomedicine 32:54-55.
14. Horrobin DF (1992): The relationship between schizophrenia and essential fatty acid and eicosanoid metabolism. Prostaglandins Leukot Essent Fatty Acids 46:71-77.
15. Hudson C, Young L, Li P, Warsh JJ (1993): CNS signal transduction in the pathophysiology and pharmacotherapy of affective disorders and schizophrenia. Synapse 13:278-293.
16. 2 associated with schizophrenia.
17. Kafka MS, van Kammen DP (1983) α-Adrenergic receptor function in schizophrenia. Arch Gen Psychiatry 40:264-270.
18. Kay S, Opler L, Fiszbein A (1987): Positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 13:261-276.
19. Morrow J, Parsons W, Roberts L (1989): Release of markedly increased quantities of prostaglandin D2 in vivo in humans following the administration of nicotinic acid. Prostaglandins 38:263-274.
20. Morrow JD, Awad JA, Oates JA, Roberts LJ (1992): Identification of skin as a major site of prostaglandin D2 release following oral administration of niacin in humans. J Invest Dermatol 98:812-815.
21. Rybakowski J, Weterle R (1991): Niacin test in schizophrenia and affective illness. Biol Psychiatry 29:834-836.
22. Sleight AJ, Koek W, Bigg DC (1993): Binding of antipsychotic drugs at alpha 1A-and alpha 1B-adrenoceptors: Risperidone is selective for the alpha 1B-adrenoceptors. Eur J Pharmacol 238:407-410.
23. Spitzer RL, Williams JBW, Gibbons M (1986): Structured Clinical Interview for DSM-III-R (SCID). New York: New York State Psychiatric Institute, Biometrics Research.
24. Whelan AM, Price SO, Fowler SF, Hainer BL (1992): The effect of aspirin on niacin-induced cutaneous reactions. J Fam Pract 34:165-168.
25. Wilkin J (1982): Chlorpropamide-alcohol flushing, malar thermal circulation index, and baseline malar temperature. Metabolism 31:948-954.
26. Wilkin J, Wilkin O, Kapp R, Donachie R, Chernosky M, Buckner J (1982): Aspirin blocks nicotìnic acid-induced flushing. Clin Pharmacol Ther 31:478-482.
27. Wilson DWS, Douglass AB (1986): Niacin skin test is not diagnostic of schizophrenia. Biol Psychiatry 21:974-977.
28. Young RC, Biggs JT, Ziegler VE, Meyer DA (1978): A rating scale for mania: Reliability, validity, and sensitivity. Br J Psychiatry 133:429-435.